OPEN MARKET SALE AGREEMENTSMOpen Market Sale Agreement • August 6th, 2020 • Eiger BioPharmaceuticals, Inc. • Biological products, (no disgnostic substances) • New York
Eiger BioPharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares of the Company’s common stock, par value $0.001 per share (the “Common Shares”), having an aggregate offering price of up to $50,000,000 on the terms set forth in this agreement (this “Agreement”).
Amendment No. 1 to the Collaboration and Supply AgreementCollaboration and Supply Agreement • August 6th, 2020 • Eiger BioPharmaceuticals, Inc. • Biological products, (no disgnostic substances)
This Amendment No. 1 (“Amendment”) is effective as of June 15, 2020 (the “Amendment Effective Date”) by and between Eiger BioPharmaceuticals, Inc., a Delaware corporation currently located at 2155 Park Boulevard, Palo Alto, CA 94306 (“Eiger”), and The Progeria Research Foundation, Inc., a 501(c)(3) not-for-profit organization currently located at 200 Lake St., Peabody MA 01960 (“PRF”) and amends the Collaboration and Supply Agreement, dated May 15, 2018, by and between Eiger and PRF (“Agreement”). Certain capitalized terms used herein but not expressly defined in this Amendment will have the meanings given in the Agreement.
